Vipul Yadav, Aileen House, Silvia Matiz, Laura E McCoubrey, Kimberly A Bettano, Leena Bhave, Meiyao Wang, Peter Fan, Siqun Zhou, Janice D Woodhouse, Eirini Poimenidou, Liu Dou, Abdul W Basit, Lily Y Moy, Robert Saklatvala, Laxminarayan G Hegde, Hongshi Yu
Janus kinase (JAK) inhibitors, such as tofacitinib (Xeljanz) and filgotinib (Jyseleca), have been approved for treatment of ulcerative colitis with several other JAK inhibitors in late-stage clinical trials for inflammatory bowel disease (IBD). Despite their impressive efficacy, the risk of adverse effects accompanying the use of JAK inhibitors has brought the entire class under scrutiny, leading to them receiving an FDA black box warning. In this study we investigated whether ileocolonic-targeted delivery of a pan-JAK inhibitor, tofacitinib, can lead to increased tissue exposure and reduced systemic exposure compared to untargeted formulations...
November 5, 2022: Pharmaceutics